Gastrointestinal bleeding can be challenging, requiring fast decision-making and efficient tools to achieve effective results. To help clinicians meet that challenge, Cook Medical launched Hemospray, an advanced treatment option for patients suffering from non-variceal bleeding in the GI tract. Hemospray represents a different approach to treat GI bleeds as it does not require the en face approach and the precise targeting of other current treatments.
Below, you’ll hear from Dr. Martin James, Queens Medical Centre UK, and Dr. John Morris, Glasgow Royal Infirmary, as they discuss the patient impact and clinical benefits they’ve experienced with this hemostatic powder.
Early adopters of Hemospray: Queens Medical Centre in Nottingham
In a program presented by UK newsreader Natasha Kaplinsky, Dr. Martin James, alongside Prof. Krish Ragunath and Deputy Sister Tara Shepherd, discuss the clinical impact of Hemospray in their facility and the confidence it has given the team when facing non-variceal GI bleeding.
This video is co-produced by ITN Productions, Cook Medical and the RSM.
Clinical case: Management of an esophageal cancer bleed using Hemospray
A patient was hospitalized for 3 days after presenting at the Glasgow Royal Infirmary with bleeding post laser therapy for advanced esophageal carcinoma. The patient required 1-3 units of blood on a daily basis. Watch as Dr. John Morris takes us through this case and how the team achieved hemostasis after treating the bleed site using Hemospray.
For more information on Hemospray, visit: hemospray.cookmedical.com
While there, you can access Hemospray case videos, FAQs, product specifications and other supporting information for you and your patients.
Dr. James was not paid for his time in the making of this film but has been a paid consultant of Cook Medical in the past.
Prof. Ragunath was not paid for his time in the making of this film.
Deputy Sister Tara Shepherd was not paid for her time in the making of this film.
Dr. Morris is a paid consultant of Cook Medical.
Summary of Clinical Data: Clinical data summary information that was, in part, the basis for granting the de novo can be found on the Cook Medical website at cookmedical.com/HemosprayData